Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.

Recruiting

VamoroloneRegistry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.

Sponsor:

Catalyst Pharmaceuticals, Inc.

Code:

NCT06564974

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 2+

Healthy Volunteers: Not accepted

Interventions

Vamorolone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Catalyst Pharmaceuticals, Inc. on 2025-04-02.